Viroptic, Lonsurf(trifluridine)
Lonsurf, Viroptic (trifluridine) is a small molecule pharmaceutical. Trifluridine was first approved as Viroptic on 1982-01-01. It is used to treat herpetic keratitis, infectious keratoconjunctivitis, and virus diseases in the USA. It has been approved in Europe to treat colorectal neoplasms.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Viroptic (generic drugs available since 1995-10-06)
CombinationsLonsurf
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| lonsurf | New Drug Application | 2020-01-14 |
| trifluridine | ANDA | 2021-08-05 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| herpetic keratitis | EFO_0007308 | D016849 | — |
| infectious keratoconjunctivitis | — | D007639 | — |
| virus diseases | — | D014777 | B34 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TIPIRACIL HYDROCHLORIDE / TRIFLURIDINE, LONSURF, TAIHO ONCOLOGY | |||
| 2026-02-22 | ODE-229 | ||
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BC: Pyrimidine analogues, antineoplastic antimetabolites
— L01BC59: Trifluridine, combinations
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AD: Antivirals, ophthalmologic
— S01AD02: Trifluridine
HCPCS
No data
Clinical
Clinical Trials
109 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Colorectal neoplasms | D015179 | 17 | 31 | 15 | — | 3 | 58 | ||
| Neoplasms | D009369 | C80 | 9 | 1 | 1 | — | — | 10 | |
| Stomach neoplasms | D013274 | EFO_0003897 | C16 | 1 | 5 | 1 | — | — | 6 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Adenocarcinoma | D000230 | 3 | 8 | — | — | 1 | 11 | ||
| Colonic neoplasms | D003110 | C18 | 2 | 6 | — | — | — | 8 | |
| Rectal neoplasms | D012004 | 4 | 4 | — | — | — | 8 | ||
| Renal cell carcinoma | D002292 | 3 | 3 | — | — | — | 6 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 4 | — | — | — | 5 |
| Cholangiocarcinoma | D018281 | C22.1 | — | 3 | — | — | — | 3 | |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 3 |
| Bile duct neoplasms | D001650 | — | 2 | — | — | — | 2 | ||
| Gallbladder neoplasms | D005706 | EFO_0004606 | C23 | — | 2 | — | — | — | 2 |
| Small cell lung carcinoma | D055752 | — | 1 | — | — | — | 1 |
Show 5 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Gastrointestinal stromal tumors | D046152 | EFO_0000505 | C49.A | 1 | — | — | — | — | 1 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 1 | — | — | — | — | 1 |
| Pancreatic ductal carcinoma | D021441 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 2 | 2 |
| Herpes simplex | D006561 | B00 | — | — | — | — | 1 | 1 | |
| Mycobacterium avium-intracellulare infection | D015270 | EFO_0007386 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRIFLURIDINE |
| INN | trifluridine |
| Description | Trifluridine is a pyrimidine 2'-deoxyribonucleoside compound having 5-trifluoromethyluracil as the nucleobase. An antiviral drug used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis. It has a role as an antiviral drug, an antimetabolite, an EC 2.1.1.45 (thymidylate synthase) inhibitor and an antineoplastic agent. It is a nucleoside analogue, an organofluorine compound and a pyrimidine 2'-deoxyribonucleoside. |
| Classification | Small molecule |
| Drug class | antivirals; antineoplastics (uridine derivatives) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=c1[nH]c(=O)n([C@H]2C[C@H](O)[C@@H](CO)O2)cc1C(F)(F)F |
Identifiers
| PDB | — |
| CAS-ID | 70-00-8 |
| RxCUI | 10803 |
| ChEMBL ID | CHEMBL1129 |
| ChEBI ID | 75179 |
| PubChem CID | 6256 |
| DrugBank | DB00432 |
| UNII ID | RMW9V5RW38 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,669 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,716 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more